Skip to main content
. Author manuscript; available in PMC: 2010 Feb 10.
Published in final edited form as: J Neurochem. 2007 Jan 4;101(1):87. doi: 10.1111/j.1471-4159.2006.04346.x

Fig. 4.

Fig. 4

Treatment with the selective CB2 agonist AM-1241, initiated at symptom onset, produces a pronounced increase in survival of G93A-SOD1 mice. (a–c) Comparison of the effects of daily treatment, initiated at symptom onset, on survival of G93A mice with (a) 5 mg/kg WIN-55 212 (n = 6), (b) 0.3 mg/kg AM-1241 (n = 14) or (c) 3.0 mg/kg AM-1241 (n = 14). The response of vehicle-treated control G93A mice (n = 9) is represented by the open squares in each panel. (d) Comparison of the survival interval of G93A mice treated daily with vehicle or the listed drugs. *, **, ***Significantly different from the vehicle-treated survival curve, p < 0.0249, 0.0017, 0.0005 (Kaplan–Meier survival analysis and log rank test (Mantel–Cox). a–bSurvival intervals that are designated with different letters are significantly different, p < 0.05 (Kruskal–Wallis test followed by a Dunn’s post hoc comparison).